Novo Nordisk Bets on Riskier Insulin Research

Danish pharmaceutical company Novo Nordisk is moving into the complex and more expensive business of inventing new forms of insulin, which would bring it closer to the riskier drug-discovery activities of the wider pharmaceutical industry.
Source: WSJ.com: Health - Category: Pharmaceuticals Tags: PAID Source Type: news